David Sinclair

Runs an ageing laboratory at Harvard and argues in Lifespan that ageing is itself a disease, driven by loss of epigenetic information, and therefore in principle treatable rather than inevitable.

The underlying research on sirtuins and cellular reprogramming is real and published. The book goes considerably further than the evidence, particularly on resveratrol and NMN supplements, and Sinclair has financial interests in companies selling in this space, which critics including other ageing researchers have raised repeatedly.

A 2024 dispute over claims made for a dog longevity product led to his resignation from a scientific federation presidency. Worth reading with the commercial context visible.